Balyasny Asset Management
BCAB icon

Balyasny Asset Management’s BioAtla BCAB Stock Holding History

Balyasny Asset Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-469
Closed -$194K – 2651
2022
Q4 		$194K Buy
+469
New +$195K ﹤0.01% 2140

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management's BCAB Position: Q1 2023 in Review

Balyasny Asset Management sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 469 shares — an estimated $194K sold.

Balyasny Asset Management first reported a position in BCAB in Q4 2022 and held it in 1 quarter. The position peaked at $194K in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

  • Balyasny Asset Management reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 469 BioAtla shares in Q1 2023, an estimated $194K.
  • Balyasny Asset Management first reported a position in BioAtla in Q4 2022 and held it in 1 quarter.
  • Balyasny Asset Management's BioAtla position peaked at $194K in Q4 2022.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.